Wang Xiaodong

Director Wang Xiaodong sold entire 41.8K share position (41,760 shares) for $10,975,315.60 on 2025-06-10 at $262.82 blended average

Wang Xiaodong, a Director at BeOne Medicines Ltd., executed 5 separate sales totaling 41,760 shares for $10,975,315.60 on a single trading day (June 10, 2025), liquidating his complete shareholding with a blended average price of $262.82. The company is trading near its 52-week high ($276.53 current price, -0.7% from the $278.38 peak) and has posted strong recent momentum (+23.0% over 30 days, +6.7% over 90 days), while the company achieved revenue growth of +55.0% year-over-year on $1,117,279,000 in latest quarterly revenue. Notably, despite strong top-line growth, the company remains unprofitable on a full-year basis and is currently trading at a substantial market capitalization ($388.1B). The complete elimination of the director's position leaves no shares outstanding post-transaction and adds to his cross-ticker track record of 20 prior sells. This total liquidation of a director-level holding warrants scrutiny into the circumstances and timing of the transaction.

Director Wang Xiaodong liquidates entire 41,760-share position at BeiGene for $9.3M across 4 sales on 2025-05-13; stock down 24.9% from 52-week high.

Wang Xiaodong, a director at BeiGene, executed four separate sales totaling 41,760 shares for $9,333,272.14 on 2025-05-13, completely exiting his position. The transactions occurred at blended average price of $223.50, while the stock now trades at $184.71, representing a 20.9% decline over the prior 90 days and 24.9% below its 52-week high of $246.04. The complete liquidation of a director's entire stake is noteworthy; however, the timing signal is unclear since Wang's prior trades at BGNE have no measurable 90-day outcomes yet (all five prior same-ticker sales on 2025-04-14 lack performance data). The sale occurs in the context of a company with strong revenue growth of 55.0% annually but persistent unprofitability on a full-year basis.

Director Wang Xiaodong sells entire 41,760-share BGNE position for $10,133,595.26 in 13 tranches on 2025-04-14

Wang Xiaodong, a director at BeiGene, executed 13 separate sales on 2025-04-14 totaling 41,760 shares for $10,133,595.26, liquidating his entire stake at a blended average price of $242.66. The current price of $184.71 represents -24.9% from the 52-week high and -14.1% decline over the past 30 days, meaning the stock has weakened significantly since the transaction. BeiGene remains unprofitable (net income of -$121,350,000.00 in the latest quarter) despite strong revenue growth of +55.0% year-over-year, reflecting execution challenges or continued investment spending ahead of profitability. The complete liquidation by a board member warrants attention, particularly given the company's operating losses and the recent price deterioration.

Director Wang Xiaodong liquidates entire 41,760-share BGNE position: 7 sales totaling $10,911,252.24 on 2025-03-18

Wang Xiaodong executed 7 separate sales totaling 41,760 shares ($10.9M) on March 18, 2025, reducing his holdings from 41,760 shares to 0 shares—a complete exit. The blended average sale price of $261.28 reflected intraday execution across prices ranging from $258.25 to $264.01. Notably, this liquidation occurred while the stock has declined 24.9% from its 52-week high of $246.04 and is trading at $184.71 today, a sharp 14.1% drop over the past 30 days and 20.9% over 90 days. The company reported negative net income of $-121,350,000.00 in the latest quarter despite strong revenue growth of 55.0% year-over-year, indicating significant profitability challenges. The insider's cross-ticker track record shows a 100.00% well-timed rate on 20 prior sells, though his 5 recent same-ticker BGNE sales on 2025-03-04 (just 14 days prior) have outcomes not yet measurable; this new liquidation follows those recent transactions in quick succession.

Director Wang Xiaodong sold 8.1K shares totaling $2.1M in 7 transactions on 2025-03-04; stock down 14.1% in 30 days, 20.9% in 90 days since sale.

Wang Xiaodong, as a director, executed 7 separate sales totaling 8,146 shares for $2,073,826.32 on 2025-03-04, liquidating his entire BGNE position. The blended average sale price of $254.58 now stands 27.3% above the current price of $184.71, and the stock has declined 14.1% over 30 days and 20.9% over 90 days since the filing date. This complete liquidation is notable given that BGNE trades at a $256.3B market cap on unprofitable fundamentals ($121.4M net loss in the latest fiscal year, though revenue grew 55.0% year-over-year). The timing of the sale—at prices near the 52-week high of $246.04—followed by substantial subsequent declines suggests the insider achieved favorable exit prices relative to current levels, though this hindsight outcome does not indicate foreknowledge. The scale of the transaction ($2.1M in a single-day filing) and full position exit merit investor scrutiny, particularly in context of the company's path to profitability and recent stock weakness.

Director Wang Xiaodong exits entire BGNE stake: 41,760 shares sold for $9,424,955.37 on 2025-02-04, -24.9% from 52-week high.

Wang Xiaodong, Director at BeiGene, executed 6 separate sales totaling 41,760 shares for $9,424,955.37 on 2025-02-04, completely liquidating his position at a blended average price of $225.69. The sales occurred across a narrow price range ($223.00–$228.04), with the largest tranche being 17,805 shares at $226.35. This complete exit is notable given the company's $1.0B quarterly revenue (+73.6% annual growth) and $256.0B market cap, though BeiGene remains unprofitable with $-121.4M net income in the latest quarter. The current stock price of $184.71 sits -24.9% below the 52-week high of $246.04 and -14.1% lower over the past 30 days, indicating the stock has declined materially since these sales were executed. The timing pattern of Wang's prior 5 trades at BGNE (all on 2025-01-07, less than a month prior) is not yet measurable, offering limited insight into whether this pattern of consistent selling reflects forward-looking assessment of the company's trajectory.

Director Wang Xiaodong sells entire 41.8K share stake in BGNE for $7.4M (avg $176.50) on 2025-01-07

Director Wang Xiaodong executed 5 separate sales totaling 41,760 shares for $7,370,514.65 on 2025-01-07, eliminating his entire shareholding at BeiGene (net change: -100.0% vs pre-transaction holdings). The sales occurred across a narrow price range ($175.46–$179.18), with a blended average of $176.50. Current price stands at $184.71, representing an immediate 4.7% opportunity cost from the execution point. BeiGene shows strong revenue growth of +73.6% year-over-year to $1,001,599,000.00 in the latest quarter, but the company remains unprofitable with net income of $-121,350,000.00 over its most recent full fiscal year. The complete liquidation of a director's position—particularly absent any scheduled trading plan disclosure—merits investor attention given the stock's volatility context (30-day change of -14.1%, 90-day change of -20.9%, trading 24.9% below 52-week high of $246.04).

Director Wang Xiaodong sells 41,760 shares of BGNE for $7.8M, eliminating entire position (100% exit)

Wang Xiaodong, a Director at BeiGene, executed 11 separate sales on 2024-12-10 totaling 41,760 shares (41.8K shares) for $7,805,105.81 ($7.8M) at prices ranging from $183.60 to $195.67, resulting in complete liquidation of his shareholding (100.0% exit). This follows five recent sell transactions at the same ticker on 2024-11-26, indicating an active disposition pattern. The sale was executed at an average price of $186.90, which is above the current price of $180.27, though still -26.7% from the 52-week high of $246.04. The company remains unprofitable despite strong revenue growth of +73.6% year-over-year, a structural contrast that may inform capital deployment decisions by insiders. The complete elimination of holdings warrants investor scrutiny given the director's prior recent activity and the company's unprofitable status.

Director Wang Xiaodong sold entire 48.4K-share position in BGNE for $9.2M across 17 trades on 2024-11-26 at blended avg $190.08

Wang Xiaodong's complete liquidation of 48,351 shares across 17 separate transactions totaling $9,190,569.91 represents a total exit from his shareholding position. The sales occurred at prices ranging from $187.15 to $191.96, with blended average price of $190.08, while the current price stands at $215.00—approximately 13% higher than the transaction prices. BeiGene remains unprofitable with net income of $-121,350,000.00 in its latest full fiscal year, though the company demonstrated strong revenue growth of +73.6% year-over-year and maintains a substantial $298.0B market capitalization. The complete elimination of holdings by a director warrants investor attention given the signal it sends about insider conviction, particularly in the context of the company's current unprofitability.